We’re excited to share that Mahya Khaki, the CEO of AiVALON Health Technologies has joined the ECHO program by the Ted Rogers Centre for Heart Research to take AiVALON's innovation to the next level! This competitive program supports startups driving innovation in cardiovascular health by providing mentorship, networking, and $250K funding through 2025's pitch competition! 🩵 💙 Exciting things ahead! 🚀 #cardiovascular #startups #hearthealth #digitalhealth #healthtech #innovation #prevention #cardiovasculardisease #entreprenuership
Director, Strategy & Translation at Ted Rogers Centre for Heart Research; Co-Founder of ECHO
We are thrilled to welcome our 2024-2025 ECHO Cohort! Last month, we admitted our 7th cohort to the ECHO program, including 13 start-up ventures from across Canada. Led by an elite and diverse group of clinicians, scientists, innovators and entrepreneurs, these promising ventures are developing ground-breaking technologies within the #cardiovascular space. We are looking forward to working with these ventures over the next 12 months and providing them with the necessary entrepreneurship training and mentorship to help them grow and succeed. AiVALON Health Technologies, AllStent, CardiActiveAI, Cath-AI, CathGraft, Elev8 and Perform, Intelligent Longevity Technologies, MyTrials.ai, ORCHID Analytics, Quthero Canada, SHARP-VT, WeavAir, Yellowbird Diagnostics, Inc. ECHO is organized and funded by the Translational Biology and Engineering Program (TBEP) – the University of Toronto component of the Ted Rogers Centre for Heart Research – in partnership with the Health Innovation Hub (H2i), a University of Toronto accelerator. https://lnkd.in/g-qbAba5